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Beginning in the 1970s, as the scientific com-
munity compiled evidence ofadverse health
outcomes associated with lead, a number of
federal regulatory and legislative efforts were
undertaken to reduce lead hazards in the
United States, including actions to limit or
eliminate the use oflead in paint, solder, and
gasoline together with thevoluntary efforts by
the food processing industry (1). These efforts
have been successful in part, as reflected by
the 72-77% dedine in mean blood lead levels
of children surveyed in the 1976 and 1991
National Health and Nutrition Examination
Surveys II andIII, respectively (2).
Nevertheless, concern remains high
regarding lead exposure and health due, in
part, to the continued high exposure ofspe-
cific sociodemographic groups and the recent
accumulation ofstudies indicating significant
relationships between low-level lead exposure
and neurologic toxicity in both children and
adults. For example, low to moderate blood
lead levels (i.e., above 10 but less than 25
pg/dl) have consistently been found to be
associatedwith decrements in cognitive func-
tioning across a wide variety ofepidemiolog-
ic studies ofchildren (1,3-5). With regard to
adults, low to moderate levels of lead in
blood have been associated with increases in
blood pressure [as reviewed by Sharp et al.
(6), Hertz-Picciotto and Croft (7), and
Schwartz (8)] as well as decreased creatinine
dearance (9,10). These studies suggest that
the prevalence ofsubdinical lead toxicity in
both children and adults is far more preva-
lent thancommonlyrecognized.
Is Blood Lead the Best
Biological Marker for
Predicting Toxicity?
In reviewing clinical studies on the effects
of low to moderate lead exposures, it is
noteworthy that the biological marker of
lead dose that has been used most common-
ly was the level of lead in blood, largely
because blood lead sampling is recognized
as a relatively easy procedure. Lead in blood
possesses a mean biological life of only
around 30 days (11); thus, it has been gen-
erally considered to reflect primarily both
ongoing steady-state exposures and relative-
ly recent elevated exposures, rather than
cumulative dose. Blood lead levels also
reflect the mobilization of lead from the
skeleton back into the circulation. This has
been reported in the occupational setting
(12), clinical studies (13), among women
with community exposure (14), among
pregnant women (15), and among adults
undergoing joint replacement (16). Thus,
blood lead serves as an indicator of both
current exogenous exposures and past expo-
sures as stored in the skeleton.
While manystudies have detected signif-
icant relationships between blood lead level
and toxicity outcomes, the correlations gen-
erally have been statistically weak and the
effect parameters relatively small [for exam-
ple, see Pocock et al. (17) on the relation-
ship ofblood lead to intelligence in children
and Hertz-Picciotto and Croft (7) on the
relationship of blood lead to blood pres-
sure]. This may be because the relationships
involved are 1) biologically weak or experi-
enced by only a small segment ofthe popu-
lations studied; 2) biologically irrelevant and
only found because of uncontrolled con-
founding by another more causal but
unmeasured factor; 3) multifactorial, where-
by the exposure-toxicity axis is mediated or
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modified by numerous inherent biologic
factors that may be poorly recognized
and/or quantitated; or 4) because blood
lead level is not a sufficiently sensitive
marker of exposure or dose to the target
organs(s) for many outcomes.
In the latter case, the error associated
with using blood lead as a proxy for a bio-
logically more relevant biomarker of lead
dose would, under most circumstances,
result in weak correlations and small effect
estimates in linear regression analyses (18).
In fact, a critical mass of indirect and
direct evidence now suggests that a cumula-
tive measure oflead dose (i.e., exposure that
is integrated over many years of time),
rather than blood lead level, may be the
most important determinant ofsome forms
oftoxicity (19,20). Much ofthese data will
be reviewed herein. As a consequence, there
is a great need in public health sciences for
the development of biologic markers that
reflect a subject's cumulative dose (defined
here as the lead dose integrated overyears to
decades).
K X-Ray Fluorescence
Until recently, epidemiologic research on
whether cumulative lead dose is the most
important determinant oflow-level leadtoxi-
cityhas been hampered by the lack ofa suit-
able noninvasive and convenient method for
estimating the cumulative lead dose of an
individual. Shed primary teeth have proven
to be a reliable measure ofcumulative lead
dose, but they are only suitable for children
atcertain ages, severelylimitingtheirapplica-
tion (21). The calcium-EDTA mobilization
test requires parenteral administration of a
drug, collection of urine for hours to days,
andmonitoring fordrugtoxicity.
However, X-ray fluorescence (XRF)
instruments, which make in vivo measure-
ments of lead levels in bone, are quite
promising in this regard (19,22,23). It has
been well established from autopsy studies
that the skeleton contains the majority
(70->95%) of the body's lead burden
(24,25). The bulk ofthat lead is contained
within long-lived compartments ofcortical
(elimination t112>5-10 years) and trabecular
(elimination t112 >1 year) bone, with com-
paratively small amounts of lead in tissue
compartments that rapidly exchange with
extracellular fluid andplasma (12,13,26-28).
Thus, measurement ofbone lead levels may
provide a surrogate of time-integrated lead
exposure.
Two types of XRF instruments exist,
LXRF and KXRF. This paper focuses on
KXRF, which has been the most widely
used and validated technology. Discussion
and critiques of LXRF may be found else-
where (29-31).
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Figure 1. Conceptual paradigms ofhow bone lead mayserve as a marker of chronic lead toxicity in adults:
bone lead as repositoryversus bone lead as source(profile for blood lead level considers only exogenous
sources of lead exposure).
Most KXRF instruments use a '09Cd or
57Co y-ray source to provoke the emission
of fluorescent photons from target tissues
that are then detected and counted. With
specialized equipment, designs, statistical
methods, and software, methods have been
developed to derive estimates ofbone lead
(in units of micrograms of lead per gram
bone mineral) with ever-improving preci-
sion and accuracy (32-34). Radiation doses
are minimal, with effective doses a small
fraction of those associated with standard
radiographs (35).
Thus, KXRF-measured bone lead has
the potential to serve as a new indicator of
dose that may be of greater relevance to
many toxicity outcomes than blood lead
level. This potential has been substantiated
in four recent cross-sectional studies. In one
of these studies, bone lead, but not blood
lead, was significantly related to dedines in
hematocrit and hemoglobin among moder-
ately lead-exposed construction workers
(36). Among middle-aged to elderly men,
bone lead, but not blood lead, was signifi-
candy related to increased odds ofdinically
relevant hypertension (37). Bone lead, but
not blood lead, was significantly related to
decreased birth weight among mothers in
Mexico City (38). And finally, among
teenagers in Pittsburgh, bone lead was asso-
ciated with increased risk for antisocial and
delinquent behavior (blood lead was not
measured in this study) (39).
Other toxicity outcomes that may bear
greater association with bone lead levels (as a
time-integrated measure ofexposure) include
cognitive performance and growth in chil-
dren and cognitive performance, kidney
function, gout, blood pressure, reproductive
toxicity, and adverse cardiovascular events in
adults. A number ofepidemiologic studies
are now in progress using KXRF to measure
bone lead to evaluate some ofthese associa-
tions, and more are being proposed,
planned, andcontemplated.
Conceptual Paradigms
Given the potential utility ofXRF in epi-
demiologic studies, it is vital to develop a
conceptual paradigm of the relationships
between bone lead levels and toxicity out-
comes. Such a paradigm would benefit from
the use of bone lead measurements in epi-
demiologic studies by identifying toxicity
outcomes that may be predicted by bone
lead level (as a surrogate ofcumulative expo-
sure), as well as the selection of bone sites
for KXRF measurement and the design of
epidemiologic studies involving bonelead.
We propose that lead in the skeleton
may serve two general roles as a marker of
chronic lead toxicity in adults. One para-
digm is that lead stored in bone presents no
toxic risk to the individual, but rather, by
being a repository for lead, serves as a proxy
for the cumulative (i.e., over years to
decades) lead dose to organs, such as the
renal and central nervous systems, that are
primary targets oflead toxicity (bone lead as
repository) (Fig. 1). Conceptually, the bone
lead as repository paradigm provides that
bone lead levels would serve as a more rele-
vant dosimeter of lead exposure and effect
in cases ofpast (though not current) chron-
ic lead exposures. In such cases, toxic effects
may be expected to be greater than would
be predicted bycurrent blood lead levels.
Asecond paradigm is that the skeleton is
an important endogenous source of lead to
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other target organs via mobilization from
bone into the circulation (bone lead as
source) (Fig. 1). The release oflead from the
skeleton could be a consequence of normal
lead flux (exchange) from bone matrix,
though it could be accelerated during peri-
ods of increased bone turnover and bone
mineral loss. This may result in relatively
prolonged elevated exposures and possibly
also serve as a source ofmore acute exposure
in cases where boneleadlevels are elevated.
With either paradigm, the relationship
between exposure and toxicity could involve
several different aspects of dose-time
response, such as direct linear, threshold, or
threshold plus a period oflatency. Finally, it
should also be considered that the skeleton
itself may be an important target organ to
circulatingandskeletal-bound lead.
While it is likely that both ofthe para-
digms presented above are operant, distin-
guishing their relative importance provides
significant implications forpublic health. If
the bone lead as repository paradigm domi-
nates, measurement of bone lead would
provide an estimation of cumulative lead
dose, but bone lead itselfwould be oflittle
toxicological importance. In contrast, ifthe
bone lead as source paradigm dominates,
important increases in lead exposure from
endogenous (i.e., skeletal) sources could
occur so that chronic lead toxicitymight be
increased by factors that increase bone
turnover, such as rapid growth [e.g., child-
hood (27,40), pregnancy and lactation
(15,41-44), senile osteoporosis (45,46),
altered endocrine states such as hyperthy-
roidism (47), and other pathological states
(48)]. Alternatively, chronic lead toxicity
might be decreased by factors that
decreased bone turnover, such as exercise
and dietary calcium (49,50). It would be
critically important to identify and measure
the influence of these factors, particularly
since it might then be possible to develop
strategies for the secondary prevention of
toxicity from mobilized bone lead.
Evidencefor bone lead as repository
versus bone lead as source. Teeth are min-
eralized tissue with properties similar to
bone. Thus, studies which demonstrate
that lead levels in shed deciduous teeth are
superior to blood lead levels in predicting
neurobehavioral impairment in children
(51) provide support for the bone lead as
repository paradigm. Additional evidence
linking measurable toxicity with bone lead
level as the measure ofexposure is provided
in studies where lead-related pathologies
have been associated with previous chronic
exposures rather than with an ongoing
insult. Examples include the focal intersti-
tial nephritis and tubular atrophy of lead
nephropathy (52 and the reduced density
of synaptic formation, reduced dendritic
arborization, and abnormal Purkinje cell
development associated with lead exposure
and neurotoxicity in animal models
(53-55). However, these and other mor-
phologic changes, including changes with a
chronic appearance, have yet to be
described in subjects that have sustained
relatively moderate lead exposures (i.e.,
blood lead levels of25-40 ig/dl).
The second paradigm is based on the
belief that the skeleton is an endogenous
source oflead to the circulation. As indicat-
ed previously, clinical and experimental
studies have provided evidence of signifi-
cant bone lead release during both normal
homeostasis (13,41,56) and following the
cessation ofchronic occupational exposures
(12,57), as well as during periods ofaccel-
erated bone turnover and mineral loss, such
as osteoporosis, pregnancy, and lactation
(41-45) and thyroid and parathyroid hor-
mone imbalances (46,47). More recently, a
studyusing endogenous stable lead isotopes
as a tracer of skeletal lead release in envi-
ronmentally exposed subjects (1-6 pg/dl
blood level) indicated that the skeleton
contributed from 40-70% of the lead in
blood (16). This suggests that blood lead
levels not only reflect recent exogenous
exposures, but that under steady-state con-
ditions they also reflect the release ofolder
accumulated lead from the skeleton.
Several ofthe above studies are also con-
sistent with a studyofautopsy specimens by
Wittmers et al. (58). In that study, the
authors reported that bone lead levels
increased linearly with age, but declined
after age 40-55 in bone sites that contained
a greater amount oftrabecular bone, like the
vertebra, ilium, and rib. This decline was
greatest in women, but a decline was also
seen in men. Because hormone depletion-
induced increases in bone resorption begin
to occur in this age group and preferentially
affect trabecular bone (59), these data sug-
gest that bone loss in the aged may lead to
notable declines in trabecular bone lead con-
tent since current environmental exposures
are substantially reduced over thosejust 1-2
decades ago (2). The cross-sectional nature
of this study limits further interpretation,
however, because differences in bone lead
could represent an exposure-cohort effect
rather than a biological effect. In other
words, the older subjects may have had
higher bone lead levels than the younger
subjects because the lead exposures the older
subjects had endured when they were young
were higher than the lead exposures current-
ly being endured by the young subjects
(exposure differences between age cohorts).
This is in contrast to assuming that older
and younger subjects had similar lead expo-
sure experiences and hypothesizing that the
higher bone lead levels observed among
older subjects were due to longer periods of
biological accumulation (biological effect).
Complementary observations were reported
by Silbergeld et al. (45) and Symanski and
Hertz-Picciotto (46) who found that post-
menopausal women had significantly higher
blood lead levels than premenopausal
women, even after controlling for age, race,
income, alcohol consumption, and other
variables. Based collectively on the above
studies, there is compellingevidence thatthe
skeleton may be a significant endogenous
source of lead to the circulation across a
wide spectrum of age and lead exposure
cohorts. However, other than a few case
reports of bone lead mobilization during
pathologic-states involving greatly increased
bone turnover such ashyperthyroidism (47),
tumorous infiltration of bone (60), and
chemotherapy (61-63), few human studies
to date have provided evidence that demon-
strates an association between bone lead
mobilization and toxicity, while no compa-
rable evidence has been published with
regard to animal studies.
Inferences on paradigmsfrom KXRF
studies. In humans, additional evidence
that may shed light on the relative impor-
tance ofbone lead as repositoryversus bone
lead as source is being generated from
research using KXRF. This evidence stems
from the ability of KXRF to take separate
measurements of lead in cortical and tra-
becular bone and provide information on
the distinct differences between these two
types ofbones in terms oflead kinetics.
Several studies, including those using
radio-tracer (64) and standard metabolic
methods (16,26,27,64), have substantiated
the greater importance of trabecular bone
over cortical bone as the predominant
skeletal source of lead to the circulation
under steady-state conditions. This impor-
tance is based largely on the elevated blood
perfusion and turnover rates of trabecular
bone. For example, in a typical individual
with a skeletal mass of 6 kg, the ratio of
trabecular to cortical bone mass is approxi-
mately 1:4. If the lead concentrations of
trabecular and cortical bone were 10 mg/kg
and 5 mg/kg, respectively [consistent in
direction with Wittmers et al. (58) and
Goldman et al. (47) among others], and
the release rate oftrabecular versus cortical
bone were 15%/year versus 3%/year [as
suggested by Leggett (27)], then the rate of
lead release from trabecular bone can be
calculated to be 1.8 mg/year, which is
almost threefold higher than the value of
0.68 mg/year calculated forcortical bone.
The relative importance of trabecular
bone to circulating lead is also based on
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investigations using KXRF. In studies of
retired leadworkers, itwas shown that blood
lead levels following cessation of exposure
correlate with trabecular bone lead levels and
not with cortical lead levels (12,57).
Chelatable lead was found to correlate with
lead in biopsies ofthevertebrae (amosdytra-
becular bone), but not KXRF-measured lead
in finger bone (which is mostly cortical
bone) (65). Fleming et al. (66) on the other
hand, found that the relationship ofKX.RF-
measured bone lead to blood among lead
smelter workers who had not worked for 10
months, as well as retired lead smelter work-
ers, was stronger for the tibia (cortical bone)
than the calcaneus (trabecular bone). One
potential explanation is that although bone
mineral density of the calcaneus has been
reported to be agood indicator ofoverall tra-
becular bone density (62'), the error for cal-
caneal measurements is generally larger than
that oftibia measurements, which may have
resulted in a more attentuated bone
lead-blood leadrelationship.
Several recent epidemiologic investiga-
tions using KXRF have targeted measure-
ments at the mid-tibia and patella bones,
taking advantage ofthe fact that these two
bone sites are almost purely cortical and tra-
becular, respectively, in nature (the patella
measurement may also be influenced by
lead concentrations in the distal and proxi-
mal ends ofthe femur and tibia, respective-
ly; both ofthese bone segments are also pre-
dominantly trabecular in nature) (224. In a
cross-sectional investigation ofmiddle-aged
to elderly men, it was found that patella
lead was superior to tibia lead in its correla-
tion with blood lead level, even after adjust-
ing for age, race, education, smoking, and
alcohol consumption (68). Among these
mostly retired men, patella lead accounted
for 70% ofthe total variance ofblood lead
that the final model could explain. In a
cross-sectional study ofpostpartum women
in Mexico City, patella lead was superior to
tibia lead in its correlation with blood lead
levels, even after adjusting for current use of
lead-glazed ceramics (one of the main
sources of environmental lead exposure in
Mexico), consumption offoods high in cal-
cium, years living in Mexico City, educa-
tion, age, smoking, and parity (69).
Thus, existing data suggest that trabec-
ular bone is the predominant bone type
providing lead back to the circulation
under steady-state and pathologic condi-
tions and that cortical bone lead levels are a
better dosimeter of long-term cumulative
lead exposure because of the long biologic
mean life oflead in that tissue (>10 years)
compared to trabecular bone (1-5 yrs)
(26,22'). Significant mobilization of lead
from trabecular bone would result in an
improved correlation between blood and
trabecular bone lead levels in the absence of
elevated current exposures, which would be
evident in epidemiologic studies investigat-
ing these parameters. Ofequal importance
is investigation of the bone lead as reposi-
tory paradigm, whereby cortical bone lead
levels are determined to evaluate cumula-
tive exposures and their relationship with
the presence ofpast or current (i.e., perma-
nent) toxicity.
Although there are only a handful of
studies ofbone lead as a predictor oftoxici-
ty that employed separate measurements of
cortical and trabecular bone, the few that
exist provide a range of intriguing and at
times apparently conflicting results. For
example, in a study ofconstruction workers
who had moderate occupational exposures
to lead, patella (trabecular) bone lead but
not tibia (cortical) bone lead, was associated
with declines in hematocrit and hemoglo-
bin (36). Similarly, in a case-control study
of middle-aged to elderly women, patella
bone lead, but not tibia bone lead, was asso-
ciated with an increased risk ofhyperten-
sion (70). In contrast, however, an investi-
gation ofmiddle-aged to elderly men found
that bone lead in the tibia and not the
patella was associated with an increased risk
ofhypertension (32'). A similar relationship
was observed in a study of birth outcomes
among women in Mexico City, where lead
in the tibia and not the patella was associat-
edwith lower birth weight (38).
These results suggest that the mecha-
nisms underlying the bone lead as repository
and bone lead as source paradigms vary in
their relative importance, depending on the
measure oftoxicity, magnitude and duration
of lead exposure, and characteristics (e.g.,
age, sex) ofthe subjects. It is also important
to recognize, however, that these contrasting
results may be due to artifacts ofexperimen-
tal technique. For example, the KXRF mea-
surement uncertainty associated with patella
(trabecular) bone measurements is usually
greater than thatoftibia (cortical) bone, due
to a lower relative mineral density. Thus, it
should be considered that tibia bone lead
may be more predictive of toxicity because
of the greater precision of those measure-
ments, rather than the biological importance
ofcortical bone.
Potential benits ofplasma lead mea-
surements. The degree to which whole
blood lead reflects the labile, toxic fraction
oflead in the circulation is not well known,
although it has been suggested that lead in
plasma provides a more kinetically respon-
sive and toxicologically relevant marker of
lead than does whole blood lead (28,71,72).
The limitations of whole blood lead mea-
surements as a marker oflead exposure and,
more importantly, as a biomarker ofreadily
labile and toxic lead have been considered
for several years (73). As indicated above, it
is known that the skeleton can contribute
lead back to the circulation, although the
nature of this relationship across varying
exposure regimens and bone metabolic
states is not known. We propose that lead
in the plasma fraction of the circulation
may provide additional (and possibly supe-
rior) information on the release oflabile,
toxic lead from the skeleton.
Until recendy, arguments substantiating
the need to evaluate plasma lead to investi-
gate bone lead release was based, in part, on
previous reports showing little or no correla-
tion betweenwholeblood andplasmalead at
low to moderate blood lead levels (e.g., 5-25
pg/dl) (74-76). Included in a number of
those reports was an apparent severalfold
variation in the relative partitioning oflead
between whole blood andplasma for agiven
whole blood lead level. More recendy, how-
ever, studies [Hernandez-Avila et al., unpub-
lisheddata; (77)] have observed aremarkably
well-defined and precise curvilinear relation-
ship between whole blood and plasma lead
levels, indicating that individual variation in
the relative distribution of lead between
whole blood and plasma is not as variable as
previously believed. These recent data have
provided a basis from which to investigate
variation in lead partitioning between whole
blood and plasma within individuals and
specifically a means to investigate the rela-
tionship between bone lead content and
plasma-whole bloodleadpartitioning.
The potential benefit ofsuch an investi-
gation is substantiated byevidence indicating
that the bloodplasma (vs. whole blood) con-
tains the most labile, biologically active frac-
tion of lead in the circulation (11,28,71).
Within the circulatory compartment, lead is
partitioned primarily between the red cell
and plasma (28,76,79,80). Nearly all of the
lead that enters the body passes through the
blood plasma, although based on recent data
(Hernandez-Avila et al. unpublished data)
from individuals withwholebloodleadlevels
between 2 and 40 pg/dl, only 0.4% ± 0.1
standard deviation (SD) ofthe whole blood
lead is contained within the plasma. Further,
studies evaluating plasma lead levels during
EDTA chelation have shown that plasma
lead reflects the movement and exchange of
endogenous lead better than whole blood
lead levels (81-83). Finally, the data of
Cavalleri and Minoia (84) on plasma and
whole blood lead levels following occupa-
tional exposures suggest that the partitioning
oflead inplasma mayvarydepending on the
type/source (i.e., chemical speciation) of
exposure. Thus, plasma lead levels may bet-
ter reflect exposures to lead of different
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chemical species, which may be ofrelevance
here if leadmobilized from theskeleton into
the circulation exists as a different bimolecu-
lar species compared to lead derived from
recent exogenous exposures.
A recently completed study of serum
lead that also employed KXRF to measure
bone lead levels bears directly on this issue.
Cake et al. (71) measured serum lead,
whole blood lead, and lead in both the
tibia (chiefly cortical bone) and calcaneus
(chiefly trabecular bone) in each of 49
active lead workers. Serum lead was mea-
sured by an inductively coupled plasma
mass spectrometer in conjunction with an
isotope dilution standardization method
developed by Bowins and McNutt (85).
Serum lead measurements were found to
correlate more strongly with both in vivo
bone lead measurements (tibia and calca-
neus) than did whole blood lead. The ratio
of serum lead to whole blood lead varied
from 0.8 to 2.5% and showed the strongest
correlation with lead in the calcaneus (tra-
becular bone).
This study further substantiates the
proposed benefit ofplasma (or serum) lead
measurements for evaluating exchange and
release of lead from the skeleton. It also is
consistent with other studies, which sug-
gest that plasma lead levels reflect the bio-
logically labile component of circulatory
lead better than does whole blood. The
quantitative importance ofthis kinetic par-
adigm can be illustrated if one takes the
example ofa typical blood sample in which
the plasma lead concentration is 0.1 sg/dl,
the red blood cell concentration is 10
jg/dl, the hematocrit is 40%, and the con-
sequent whole blood lead concentration is
4.06 pg/dl (Fig. 2). A threefold rise in plas-
ma lead concentration to 0.3 pg/dl would
greatly increase the lead available to cross
cell membranes; however, the increase in
whole blood lead concentration (to 4.18
pg/dl) concentration would be negligible.
Despite the apparent benefit ofmeasur-
ing plasma (or serum) lead levels in the
evaluation of endogenous lead movement
and exchange, fewstudies have demonstrat-
ed the capability for routinely making those
measurements. The primary reasons for this
are the difficulties associated with avoiding
lead contamination during the collection,
processing, and analyses ofclinical samples
that may contain <0.05 1ig Pb/dl and the
difficulties associated with performing
analyses with the accuracy and precision
necessary to suitably evaluate interindivid-
ual or interpopulation differences in lead
levels (71,72,75,86). In addition to the
paramount concern for sample lead conta-
mination from external sources, there is also
concern for lead contamination of plasma
(or serum) from hemolysis during blood
collection and separation, as recently
demonstrated (78). Because lead in blood is
partitioned predominantly (>98%) with
erythrocytes, the hemolysis that often
occurs during blood collection and separa-
tion may contribute relatively substantial
amounts oflead to the separated plasma (or
serum) fraction, even in cases where notice-
able hemolysis (i.e., reddening of plasma)
does not occur. This concern has not yet
been systematically evaluated although,
together with external lead contamination,
it may be an important contributor to the
amount and variability of lead in plasma
reported in many studies. An additional
technical concern involves standardizing the
protocol in terms oftime ofday and fasting
because the plasma is a small and rapidly
exchangeable lead compartment. Even
small discrete exposures, such as a meal,
may appear as temporal spikes in the plas-
ma and urine; thus, standardizing the tim-
ing ofsample collection is ofimportance to
measuring basal plasmalead levels.
Strategiesfor distinguishing between
paradigms. To identify the relative impor-
tance ofthe two paradigms by which bone
lead may serve as a biological marker of
exposure and toxicity, several strategies
may be useful. First, animal studies may be
undertaken that can shed insight both into
the biokinetics of lead concentrations in
bone, plasma, blood, and target organs, as
well as the relative impact oflead dose bio-
markers in predicting forms of toxicity.
Radioisotope tracer methods comparing
stable isotope ratios of lead in plasma,
bone, and blood may also prove useful.
Toxicity studies would only be useful in so
far as animal models have been developed
for such outcomes, which could be said, for
example, of hypertension (87) and neu-
robehavioral effects (88,89). Animal studies
should use environmentally relevant lead
exposure regimens. Excessively elevated
acute or chronic exposures may themselves
result in direct permanent damage to lead-
sensitive target organs, thereby compromis-
ing the ability to evaluate secondary toxici-
ty due to mobilized bone lead. Suitable
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animal models also exist for various
pathologies of skeletal physiology (e.g.,
hormone depletion-induced osteopenia)
that could shed light on whether bone
turnover modifies the toxicity of lead
released from bone.
Epidemiologic studies are, of course,
time consuming and costlyand mostly lim-
ited to observational investigations.
However, using KXRF to measure bone
lead and incorporating biological markers
ofbone resorption and/or turnover, as well
as densitometry methods, could significant-
ly enhance the ability of epidemiologic
studies to provide insights in this area.
Data indicating that high bone turnover
increases the amount oftoxic lead released
from bone would constitute prima facie
evidence that bone lead as source is an
important mechanism of toxicity. Ideally,
clinical studies should be prospective in
design and include subjects that represent a
broad range of lead exposures to evaluate
rates oflead accumulation in bone. In cases
where this is impractical, cross-sectional
designs may be employed, taking into
account, if necessary, different baseline
exposure levels suffered by the older sub-
jects when theywere younger.
Identifying a Marker for Bone
Lead Mobilization
In considering these types ofstudies, another
issue that arises is identifying metrics that
can be used to estimate bone lead mobiliza-
tion. On first glance, it would seem that by
takingrepeated in vivomeasures ofbonelead
levels in a longitudinal design, we may
assume that declines in bone lead directly
reflect mobilization ofbone lead into the cir-
culation. However, because KXRF instru-
ments measure bone lead levels relative to
bone mineral, concurrent changes in bone
mineral content must also be considered. For
instance, a bone site that is primarily under-
going mineral resorption and little formation
would experience similar declines in bone
mineral and bone lead, with little or no
apparent net change in bone lead concentra-
tion (in micrograms Pb per gram bone min-
eral) (Fig. 3B). Thus, theabsenceofadecline
0.3 .g/dl
Concentration
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Figure 2. Paradigm of lead kinetics showing how a threefold rise in plasma lead concentration without a
rise in red blood cell lead concentration would cause a negligible rise in whole blood lead concentration.
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in bone lead concentration at the measured
site would be incorrectly interpreted as no
net loss ofbone lead. (This scenario assumes
that both bone mineral and bone lead are
resorbed and released from bone with equal
efficiency, although this is not actually
known.) Conversely, a net dedine in bone
lead concentration would occur during min-
eral turnover if there were a simultaneous
formation ofbone mineral thatwas relatively
deplete oflead (because oflow external lead
exposure and therefore low circulating lead)
and resorption ofbone mineral thatwas rela-
tivelyrich inlead (Fig. 3C).
Within this conceptual framework,
measurement of bone mineral density
could provide some benefit because miner-
al density reflects the net balance of both
bone formation and resorption. The
dynamic relationship between bone forma-
tion and resorption must be considered
when interpreting measured changes in
bone density since apparent reductions in
mineral density can arise from both a
reduction in formation with ongoing
resorption, ongoing formation with
increased resorption, or a combination of
the two-all ofwhich could result in dif-
ferent apparent versus actual amounts of
bone lead release.
Assuming that the mobilization ofbone
lead into the circulation is the parameter of
most interest to be measured, a specific
marker of bone resorption should be mea-
sured. Several urinary markers of bone
resorption are available, including urinary
calcium, hydroxyproline (HYP), pyridino-
line cross-links (PYD), and, most recently,
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the cross-linked N-telopeptide oftype I col-
lagen (NTX). Among these, urinary NTX
appears to be the most promising because
of evidence indicating its specificity for
bone turnover. Although calcium, HYP,
and PYD are components of bone, all of
these markers are found in tissues other
than bone (90-92). HYP also undergoes
metabolism in the liver (91,92), rendering
levels in urine even less reflective of bone
resorption. Urinary NTX, on the other
hand, is derived specifically from bone col-
lagen degradation and is not metabolized
(93). Rosen et al. (94) recently demonstrat-
ed that creatinine-adjusted urinary NTX
levels are more responsive to acute thyroid
hormone-induced increases and bisphos-
phonate-induced decreases in bone resorp-
tion than either PYD or HYP, thereby sup-
porting NTX levels as the most accurate
and specific biological marker of bone
turnover available.
Summary and Conclusions
Several lines ofevidence have converged to
indicate that skeletal lead burden may be a
biological marker oflead dose that is more
useful than whole blood lead in predicting
some forms oftoxicity arising from chronic
low to moderate lead exposure. KXRF has
emerged as a valuable tool for making in
vivo measurements of skeletal lead in epi-
demiologic studies. Here, we have advanced
two conceptual paradigms, the bone lead as
repository for cumulative lead exposure par-
adigm and the bone lead as source para-
digm, to explain how skeletal lead burden
may serve as a predictor ofchronic toxicity.
If the latter paradigm predominates over
the former, factors that influence bone
turnover, and therefore bone lead mobiliza-
tion, may modify the toxicity of lead that
has accumulated in the skeleton over time.
Strategies for distinguishing the relative
importance of the two paradigms in epi-
demiologic studies include making separate
measurements of trabecular and cortical
bone lead and incorporating markers of
bone turnover and measurements of bone
mineral status. In addition, applying tech-
niques for measuring lead in plasma may be
important in so far as plasma lead may rep-
resent a more toxicologically relevant com-
ponent ofcirculating lead than does whole
blood, with a special relationship to bone
lead stores that may help to explain the
mechanism(s) ofbone lead toxicity. Further
research in these areas is underway.
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